2-[4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenyl]-1,3-thiazole | 938460-51-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-[4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenyl]-1,3-thiazole
• 英文别名: DRM101
• CAS: 938460-51-6
• 化学式: C₁₆H₁₀IN₃S
• 分子量: 403.246
• InChiKey: NBRKFUJJCIGUKR-UHFFFAOYSA-N

物化性质

• 熔点：
  240-241 °C
• 密度：
  1.76±0.1 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.8
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  58.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  2-溴-4'-氰基苯乙酮 在 盐酸 、 碳酸氢钠 、 三乙胺 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 38.0h， 生成 2-[4-(6-iodoimidazo[1,2-a]pyridin-2-yl)phenyl]-1,3-thiazole
  参考文献：
  名称：

  Synthesis and biological evaluation of novel radioiodinated imidazopyridine derivatives for amyloid-β imaging in Alzheimer’s disease

  摘要：

  Non-invasive detection for amyloid-beta peptide (A beta) deposition has important significance for the early diagnosis and medical intervention for Alzheimer's disease (AD). In this study, we developed a series of imidazopyridine derivatives as potential imaging agents for single-photon emission computed tomography (SPECT). Two of them, compounds DRK092 and DRM106, showed higher affinity for synthetic human A beta 1-40 fibrils than did the well-known amyloid-imaging agent IMPY. A metabolite analysis revealed brain-permeable radioactive metabolites of I-125-labeled DRK092 and IMPY; no radioactive metabolites from I-125-labeled DRM106 ([I-125]DRM106) were detected. In addition, in vitro autoradiography clearly demonstrated specific binding of [I-125]DRM106 in the hippocampal region of AD enriched with A beta plaques. Thus, our results strongly suggested that compound DRM106 can be used as an imaging agent for SPECT to detect A beta deposition in AD brain. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.05.043

文献信息

• Diagnostic and remedy for disease caused by amyloid aggregation and/or deposition
  申请人：Fujifilm Ri Pharma Co., Ltd.

  公开号：US08022075B2

  公开（公告）日：2011-09-20

  To provide a diagnostic drug which binds specifically to an amyloid aggregate and/or an amyloid deposit, to thereby realize imaging and quantification of a disease caused by amyloid aggregation and/or deposition. The invention provides a compound represented by formula (1): (wherein X1 represents an optionally substituted bicyclic heterocyclic group; X2 represents a hydrogen atom, a halogen atom, or a chelate-forming group; ring A represents a benzene ring or a pyridine ring; and ring B represents an optionally substituted 5-membered aromatic heterocyclic group which is bonded to the benzene ring or the pyridine ring via a carbon atom of ring B), a salt thereof, a solvate of any of these, or a transition metal coordination compound of any of these, and a diagnostic, preventive, or therapeutic drug containing the same.

  提供一种特异性结合到淀粉样聚集体和/或淀粉样沉积物的诊断性药物，从而实现淀粉样聚集和/或沉积引起的疾病的成像和定量。本发明提供了由式（1）表示的化合物：（其中X1代表可选取代的双环杂环基；X2代表氢原子，卤素原子或螯合形成基团；环A代表苯环或吡啶环；环B代表可选取代的5-成员芳香杂环基，通过环B的碳原子与苯环或吡啶环连接），其盐，任何这些的溶剂化合物或过渡金属配合物，以及含有该化合物的诊断性、预防性或治疗性药物。
• DIAGNOSTIC AND REMEDY FOR DISEASE CAUSED BY AMYLOID AGGREGATION AND/OR DEPOSITION
  申请人：Fujifilm RI Pharma Co., Ltd.

  公开号：EP1956013B1

  公开（公告）日：2016-04-13
• US8022075B2
  申请人：——

  公开号：US8022075B2

  公开（公告）日：2011-09-20